Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A1 | P04798 | 9/20 | 0.68 |
| ▸ | CYP1B1 | Q16678 | 9/20 | 0.68 |
| ▸ | P4HB | P07237 | 2/20 | 0.62 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.60 |
| ▸ | MAOB | P27338 | 5/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3732309 | 0.92 | CYP1A1 (0.68) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL30384249 | 0.86 | CXCL12 (0.71) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL3972645 | 0.86 | CXCL12 (0.71) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL30384684 | 0.86 | CXCL12 (0.71) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL3972646 | 0.86 | CXCL12 (0.71) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL3967732 | 0.83 | CYP1A1 (0.68) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL3967735 | 0.83 | CYP1A1 (0.68) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL11816722 | 0.82 | CYP1A1 (0.87) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL11816718 | 0.82 | CYP1A1 (0.87) | CYP1A1CYP1B1P4HBCXCL12MAOB | |
| SCHEMBL15807363 | 0.81 | CYP1B1 (1.00) | CYP1A1CYP1B1P4HBCXCL12MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114867-B1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2012-12-12 | — | — | EP | disclosed |
| US-7829563-B2 | Aminoamides as orexin antagonists | HOFFMANN-LA ROCHE INC. (US) | 2010-11-09 | — | — | US | disclosed |
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HOFFMANN-LA ROCHE, INC. | 2008-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221166-A1 | AMINOAMIDES AS OREXIN ANTAGONISTS | HCRTR1, HCRTR2, HRH3 | CYP1A1 1184/4885CYP1B1 976/4885P4HB 4731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.